<DOC>
	<DOCNO>NCT02289378</DOCNO>
	<brief_summary>This open-label , phase II study evaluate efficacy safety biweekly docetaxel , Oxaliplatin de Gramont regimen unresectable gastric adenocarcinoma first-line therapy .</brief_summary>
	<brief_title>Dose-dense Biweekly Docetaxel , Oxaliplatin 5-fluorouracil First-line Treatment Advanced Gastric Cancer</brief_title>
	<detailed_description>Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two week</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Signed write informed consent Patients histologically cytologically confirm unresectable gastric adenocarcinoma whose ECOG performance status 02 Presence measurable disease radiographic study ( include CT MRI scan , chest xray ) physical examination At least 3 week since last major surgery At least 12 month since last adjuvant chemotherapy At least 6 week since prior radiotherapy provide extent site radiotherapy field mark bone marrow suppression NOT expect Patients receive palliative radiotherapy must recover reversible toxic effect e.g . nausea vomit cause radiation field Patients reproductive potential must use effective BC Required Screening Laboratory Criteria : Hemoglobin 90g/L WBC 3.5 x 109/L Neutrophils 1.5 x 109/L Platelets 100 x 109/L Creatinine 133 umol/L creatinine clearance 60 mL/min A probable life expectancy least 6 month Brain metastasis Female childbearing potential , pregnancy test positive Concomitant malignancy previous malignancy gastric cancer within last five year , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , low grade prostate cancer Active infection Concurrent severe medical problem unrelated malignancy , would significantly limit full compliance study expose patient extreme risk Sexually active patient refuse practice adequate contraception ; Patients condition might affect absorption oral drug ( example intermittent obstruction ) unless discuss agreed principal investigator History grade 3 4 toxicity fluoropyrimidines</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>